Trial Profile

An Open-label Multicenter Study to Assess Response to COVID-19 Vaccine in Participants With Multiple Sclerosis Treated With Ofatumumab 20 mg Subcutaneously

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 24 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ofatumumab (Primary) ; Elasomeran; Glatiramer acetate; Interferon; Tozinameran
Indications Multiple sclerosis
Focus Pharmacodynamics
Sponsors Novartis Pharmaceuticals

Most Recent Events

17 Jun 2024 Status changed from completed to discontinued (Reason the study was stopped: Trial was terminated for business reasons. There has been no change in the benefit/risk profile of ofatumumab.)
06 Feb 2024 Status changed from discontinued to completed.
15 Sep 2023 Status changed from recruiting to discontinued.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com